Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.52 |
| ▸ | IDO1 | P14902 | 3/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | AGXT | P21549 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2457582 | 0.97 | IDO1 (0.54) | LOXL2IDO1TAAR1MAOBCA12 | |
| SCHEMBL27722325 | 0.84 | LOXL2 (0.44) | LOXL2IDO1TAAR1MAOBHRH3 | |
| SCHEMBL1765201 | 0.82 | PNMT (0.46) | LOXL2IDO1TAAR1MAOB | |
| SCHEMBL19383085 | 0.82 | LOXL2 (0.42) | LOXL2IDO1TAAR1MAOB | |
| SCHEMBL2039301 | 0.82 | LOXL2 (0.42) | LOXL2IDO1TAAR1MAOB | |
| SCHEMBL4162524 | 0.82 | LOXL2 (0.42) | LOXL2IDO1TAAR1MAOB | |
| SCHEMBL12524829 | 0.82 | CA12 (0.55) | LOXL2IDO1TAAR1MAOBCA12 | |
| SCHEMBL31614540 | 0.82 | LOXL2 (0.42) | LOXL2IDO1TAAR1MAOB | |
| SCHEMBL27758807 | 0.82 | LOXL2 (0.42) | LOXL2IDO1TAAR1MAOB | |
| SCHEMBL27913532 | 0.82 | LOXL2 (0.42) | LOXL2IDO1TAAR1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378225-B2 | Process for manufacturing (S)-3-hydroxy-1-(1H-indol-5-yl)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide | MERCK PATENT GMBH (DE) | 2025-08-05 | — | — | US | claimed |
| WO-2025137551-A1 | AMINE PURIFICATION IN A CARBON CAPTURE METHOD USING MOF BODIES | SCHLUMBERGER TECHNOLOGY CORPORATION (US) | 2025-06-26 | — | — | WO | claimed |
| CN-115458724-B | High-energy-density composite positive electrode material and preparation method and application thereof | 中国科学院深圳先进技术研究院 | 2025-03-25 | — | — | CN | claimed |
| CN-114026069-B | Process for the manufacture of (S) -3-hydroxy-1- (1H-indol-5-yl) -2-oxo-pyrrolidine-3-carboxylic acid 3, 5-difluoro-benzylamide | 默克专利股份公司 | 2025-01-07 | — | — | CN | claimed |
| CN-116410106-B | Benzamide HBV capsid protein inhibitor and preparation method and application thereof | 山东第二医科大学 | 2024-12-06 | — | — | CN | claimed |
| WO-2024221958-A1 | PREPARATION METHOD FOR MODIFIED POLYETHERSULFONE/POLYETHERIMIDE POLYMER ALLOY | 深圳先进技术研究院 | 2024-10-31 | — | — | WO | claimed |
| EP-3994134-B9 | PROCESS FOR MANUFACTURING (S)-3-HYDROXY-1-(1H-INDOL-5-YL)-2-OXO-PYRROLIDINE-3-CARBOXYLIC ACID 3,5-DIFLUORO-BENZYLAMIDE | MERCK PATENT GMBH (DE) | 2024-06-26 | — | — | EP | claimed |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | claimed |
| EP-3994134-B1 | PROCESS FOR MANUFACTURING (S)-3-HYDROXY-1-(1H-INDOL-5-YL)-2-OXO-PYRROLIDINE-3-CARBOXYLIC ACID 3,5-DIFLUORO-BENZYLAMIDE | MERCK PATENT GMBH (DE) | 2024-01-24 | — | — | EP | claimed |
| CN-117298108-A | Androgen receptor and glucocorticoid receptor dual-target inhibitor and application thereof | 浙江师范大学 | 2023-12-29 | — | — | CN | claimed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | claimed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | claimed |
| EP-1984334-A2 | INDOLE-3-CARBOXYLIC ACID AMIDE, ESTER, THIOAMIDE AND THIOL ESTER COMPOUNDS BEARING ARYL OR HETEROARYL GROUPS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | Allergan, Inc. (US) | 2008-10-29 | — | — | EP | claimed |
| US-20080182870-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-07-31 | — | — | US | claimed |
| WO-2008077651-A1 | PYRIDO(3,2-D)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-07-03 | — | — | WO | claimed |
| EP-1519932-B1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LTD (GB) | 2007-10-03 | — | — | EP | claimed |
| WO-2007095561-A2 | INDOLE-3-CARBOXYLIC ACID AMIDE, ESTER, THIOAMIDE AND THIOL ESTER COMPOUNDS BEARING ARYL OR HETEROARYL GROUPS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2007-08-23 | — | — | WO | claimed |
| US-20070191313-A1 | INDOLE-3-CARBOXYLIC ACID AMIDE, ESTER, THIOAMIDE AND THIOL ESTER COMPOUNDS BEARING ARYL OR HETEROARYL GROUPS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. | 2007-08-16 | — | — | US | claimed |
| CN-1558898-A | Antiviral agent | ��Ұ����ҩ��ʽ���� | 2004-12-29 | — | — | CN | claimed |
| EP-1422218-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2004-05-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | LOXL2 113/4885IDO1 481/4885TAAR1 1127/4885 |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | LOXL2 485/4885IDO1 3872/4885TAAR1 3840/4885 |
| US-12378225-B2 | Process for manufacturing (S)-3-hydroxy-1-(1H-indol-5-yl)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide | ALDH18A1, HPD, KMO | LOXL2 1896/4885IDO1 34/4885TAAR1 3156/4885 |
| US-20070191313-A1 | INDOLE-3-CARBOXYLIC ACID AMIDE, ESTER, THIOAMIDE AND THIOL ESTER COMPOUNDS BEARING ARYL OR HETEROARYL GROUPS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | S1PR3, S1PR1, S1PR2 | LOXL2 1300/4885IDO1 12/4885TAAR1 23/4885 |
| US-20080182870-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | PNPO, DPYD, PNP | LOXL2 2266/4885IDO1 343/4885TAAR1 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.